Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

1143 result(s) found, displaying 326 to 350

  • AusPAR: Trabectedin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Trabectedin

  • AusPAR: Ad26.COV2.S

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ad26.COV2.S

  • AusPAR: Filgotinib maleate

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Filgotinib maleate

  • AusPAR: Baricitinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Baricitinib

  • AusPAR: Durvalumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Durvalumab

  • AusPAR: Follitropin alfa

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Follitropin alfa

  • AusPAR: Mogamulizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Mogamulizumab

  • AusPAR: Olaparib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Olaparib

  • AusPAR: Omalizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Omalizumab

  • AusPAR: Adalimumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Adalimumab

  • AusPAR: Rituximab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Rituximab

  • AusPAR: Forxiga

    Australian public assessment report (AusPar)
    Forxiga (dapagliflozin) has been approved for the treatment of symptomatic heart failure with reduced ejection fraction, as an adjunct to standard of care therapy, in adults.

  • AusPAR: Guselkumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Guselkumab

  • AusPAR: Ciclosporin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ciclosporin

  • AusPAR: Labetalol hydrochloride

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Labetalol hydrochloride